Pilot Test of Patient Decision Aid for Opioid Use Disorder

In response to RFA-DA-18-005 (Expanding Medication Assisted Treatment for Opioid Use
Disorders in the Context of the SAMHSA Opioid STR Grants, R21/R33), this project will develop
and test a patient decision support tool called Patient Decision Aid for Medication-Assisted
Treatment (PtDA-MAT) for use in the CA H&SS. The PtDA-MAT is designed to (1) improve patient
knowledge and involvement and to subsequently improve treatment adherence and outcomes and
(2) to support clinicians in informing and communicating with their patients with OUD along a
continuum of care. The project will conduct 1 year of R21 to develop and pilot-test the
PtDA-MAT to facilitate shared decision making in CA H&SS, followed by 3 years of R33 to
assess the effectiveness of the PtDA-MAT in a randomized controlled trial.

The aims of the current study phase (R21) are: Aim 1. Develop a patient decision aid
(PtDA-MAT) by incorporating best available scientific evidence on MAT as well as feedback
from patients and clinical providers related to clinical priorities, perceived utility, and
acceptability; Aim 2. Conduct pilot testing of the PtDA-MAT in an iterative process guided by
an expert panel and involving key stakeholders (e.g., patients, physicians, policymakers) and
field-testing.

Inclusion Criteria:

- Opioid Use Disorder diagnosis and agreement to follow study procedures (including
permission to share medical records and other administrative records)

Exclusion Criteria:

- Significant or unstable medical or psychiatric illness that may interfere with study
participation